Results 151 to 160 of about 30,153 (204)
Some of the next articles are maybe not open access.
Current Medical Research and Opinion, 2001
The new non-steroidal and steroidal aromatase inhibitors are at least as effective as megestrol acetate (MA) as second-line hormonal agents in postmenopausal women with breast cancer. However, they are superior to MA in terms of tolerability and adverse effects.
G H, Cunnick, K, Mokbel
openaire +4 more sources
The new non-steroidal and steroidal aromatase inhibitors are at least as effective as megestrol acetate (MA) as second-line hormonal agents in postmenopausal women with breast cancer. However, they are superior to MA in terms of tolerability and adverse effects.
G H, Cunnick, K, Mokbel
openaire +4 more sources
Aromatase and aromatase inhibitors
Breast Cancer, 2001Aromatase inhibition provides both paracrine/intracrine and endocrine treatment. Recent accumulated data clarified that 3rd generation aromatase inhibitors potently suppress intratumoral estrogen synthesis particularly in postmenopausal patients. In the 2nd-line treatment for metastatic breast cancer patients, aromatase inhibitors achieved results ...
M, Toi, H, Bando, S, Saji
openaire +2 more sources
Pharmacogenetics of Aromatase Inhibitors
Pharmacogenomics, 2012Aromatase inhibitors (AIs) are an important class of endocrine drugs used in the treatment of early and advanced breast cancer in postmenopausal women. A number of studies have taken candidate approaches to assess the role of variants in genes encoding enzymes important in AI metabolism, notably CYP19A1 (aromatase), in AI response.
Hadfield, Kristen D. +1 more
openaire +3 more sources
The Journal of Steroid Biochemistry and Molecular Biology, 1999
Inhibitors of aromatase (estrogen synthetase) have been developed as treatment for postmenopausal breast cancer. Both steroidal substrate analogs, type I inhibitors, which inactivate the enzyme and non-steroidal competitive reversible, type II inhibitors, are now available.
A, Brodie, Q, Lu, B, Long
openaire +2 more sources
Inhibitors of aromatase (estrogen synthetase) have been developed as treatment for postmenopausal breast cancer. Both steroidal substrate analogs, type I inhibitors, which inactivate the enzyme and non-steroidal competitive reversible, type II inhibitors, are now available.
A, Brodie, Q, Lu, B, Long
openaire +2 more sources
A photoaffinity inhibitor of aromatase
Steroids, 1982Several 7 alpha-substituted 4-androstene-3,17-diones are potent inhibitors of the biosynthesis of estrogens, with the most effective being 7 alpha-(4'-amino)phenylthio-4-androstene-3,17-dione. An azide derivative of this 7 alpha-thioether compound has been prepared as a potential photoaffinity inhibitor.
R W, Brueggemeier +2 more
openaire +2 more sources
Arthralgia and aromatase inhibitors
Joint Bone Spine, 2014Joint Bone Spine - In Press.Proof corrected by the author Available online since mercredi 14 aout ...
Daniel, Wendling +4 more
openaire +2 more sources
Toxicity of Aromatase Inhibitors
Seminars in Oncology, 2006Adjuvant hormonal therapy in hormone receptor-positive breast cancer is used for the prevention of disease recurrence and prolongation of survival. Aromatase inhibitors are increasingly being used for this purpose. Numerous studies now reveal their benefits over tamoxifen while demonstrating a markedly different toxicity profile.
Pandya, Naushira, Morris, G J
openaire +3 more sources
American Journal of Clinical Oncology, 1995
To review the aromatase inhibitors with emphasis on the newer agents that are being developed for the treatment of metastatic breast cancer. Review of English literature over the past 5 years using Med-Line and Cancer-Line computer search. All pertinent articles were included for this review.
N K, Ibrahim, A U, Buzdar
openaire +2 more sources
To review the aromatase inhibitors with emphasis on the newer agents that are being developed for the treatment of metastatic breast cancer. Review of English literature over the past 5 years using Med-Line and Cancer-Line computer search. All pertinent articles were included for this review.
N K, Ibrahim, A U, Buzdar
openaire +2 more sources
Aromatase inhibitors in pediatrics
Nature Reviews Endocrinology, 2011Aromatase, an enzyme located in the endoplasmic reticulum of estrogen-producing cells, catalyzes the rate-limiting step in the conversion of androgens to estrogens in many tissues. The clinical features of patients with defects in CYP19A1, the gene encoding aromatase, have revealed a major role for this enzyme in epiphyseal plate closure, which has ...
Wit, J.M., Hero, M., Nunez, S.B.
openaire +3 more sources
Expert Opinion on Therapeutic Patents, 2002
Endocrine treatment is at the core of therapies against early and advanced breast cancer. Modulators of the estrogen receptor have monopolized the field, offering durable clinical responses with an excellent tolerability profile. The benefits of endocrine therapy, however, are limited to estrogen receptor positive patients.
Simonida Grubjesic +2 more
openaire +2 more sources
Endocrine treatment is at the core of therapies against early and advanced breast cancer. Modulators of the estrogen receptor have monopolized the field, offering durable clinical responses with an excellent tolerability profile. The benefits of endocrine therapy, however, are limited to estrogen receptor positive patients.
Simonida Grubjesic +2 more
openaire +2 more sources